CIK 0001437402 · Large accelerated filer
ARDELYX, INC.
Sign in to watch- Ticker
- ARDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 510-745-7047
- Business address
- 34175 ARDENWOOD BLVD., FREMONT, CA, 94555
- Former names
- NTERYX INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $486,197
- in 8 filings
Net −$486,197. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- RAAB MICHAEL −$226K President & CEO sold 3% of stake
- Bishop John E −$76K See Remarks sold 6% of stake
- Brady James Parker −$58K Chief Human Resources Officer sold 6% of stake
- Williams Laura A −$41K Chief Patient Officer sold 3% of stake
- Foster Eric Duane −$33K Chief Commercial Officer sold 2% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-08 | Williams Laura A Chief Patient Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −0 | 62,000 | ||
| 2025-11-21 | GRAMMER ELIZABETH A See Remarks | Sale | −5,995 | $5.54 | $33K | 299,895 |
| 2025-11-21 | RAAB MICHAEL President & CEO | Sale | −46,887 | $5.54 | $260K | 1,455,363 |
| 2025-11-21 | Kelliher Mike See Remarks | Sale | −5,560 | $5.54 | $31K | 271,181 |
| 2025-11-21 | Williams Laura A Chief Patient Officer | Sale | −6,426 | $5.54 | $36K | 359,896 |
| 2025-11-21 | Foster Eric Duane Chief Commercial Officer | Sale | −5,814 | $5.54 | $32K | 295,684 |
| 2025-11-21 | Reilly Joseph James See Remarks | Sale | −11,086 | $5.54 | $61K | 108,914 |
| 2025-08-26 | Williams Laura A Chief Patient Officer | Option exercise 10b5-1 | +50,000 | $0.99 | $50K | 446,322 |
| 2025-08-26 | Williams Laura A Chief Patient Officer | Sale 10b5-1 | −50,000 | $6.12 | $306K | 396,322 |
| 2025-08-26 | Williams Laura A Chief Patient Officer | Sale 10b5-1 | −30,000 | $6.12 | $184K | 366,322 |
| 2025-08-26 | Williams Laura A Chief Patient Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −50,000 | 112,000 | ||
| 2025-08-21 | Kelliher Mike Chief Business Officer | Sale | −5,417 | $5.93 | $32K | 276,741 |
| 2025-08-21 | Williams Laura A Chief Patient Officer | Sale | −6,261 | $5.93 | $37K | 396,322 |
| 2025-08-21 | Renz Justin A Chief Financial Officer | Sale | −7,037 | $5.93 | $42K | 409,052 |
| 2025-08-21 | RAAB MICHAEL President & CEO | Sale | −45,687 | $5.93 | $271K | 1,502,250 |
| 2025-08-21 | GRAMMER ELIZABETH A See Remarks | Sale | −5,841 | $5.93 | $35K | 305,890 |
| 2025-08-21 | Foster Eric Duane Chief Commercial Officer | Sale | −15,308 | $5.93 | $91K | 301,498 |
| 2025-06-18 | Bazemore Robert B Director | Grant or award | +41,551 | 41,551 | ||
| 2025-06-18 | Bazemore Robert B Director | Grant or award · Stock Option (Right to Buy) | +54,059 | 54,059 | ||
| 2025-06-18 | Rodgers Richard J Director | Grant or award | +21,468 | 371,992 |
Page 7 of 11 · 206 trades